Natixis Advisors
GPCR icon

Natixis Advisors’s Structure Therapeutics GPCR Stock Holding History

Natixis Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,459
Closed -$392K – 1633
2024
Q4 		$392K Sell
14,459
-12,216
-46% -$433K ﹤0.01% 1520
2024
Q3 		$1.17M Buy
26,675
+7,670
+40% +$297K ﹤0.01% 1245
2024
Q2 		$746K Buy
19,005
+4,321
+29% +$177K ﹤0.01% 1337
2024
Q1 		$629K Sell
14,684
-874
-6% -$36.9K ﹤0.01% 1335
2023
Q4 		$634K Buy
+15,558
New +$892K ﹤0.01% 1340

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Natixis Advisors's GPCR Position: Q1 2025 in Review

Natixis Advisors sold out of Structure Therapeutics (GPCR) in Q1 2025, closing a stake of 14,459 shares — an estimated $392K sold.

Natixis Advisors first reported a position in GPCR in Q4 2023 and held it in 5 quarters. The position peaked at $1.17M in Q3 2024. 150 funds tracked by Wall St. Rank hold GPCR as of Q1 2025.

  • Natixis Advisors reported no remaining Structure Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Natixis Advisors sold 14,459 Structure Therapeutics shares in Q1 2025, an estimated $392K.
  • Natixis Advisors first reported a position in Structure Therapeutics in Q4 2023 and held it in 5 quarters.
  • Natixis Advisors's Structure Therapeutics position peaked at $1.17M in Q3 2024.
  • 150 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2025.

Based on Natixis Advisors's 13F filing for Q1 2025, filed 8 May 2025.